Terri R Fried1, Elizabeth H Bradley, Virginia R Towle. 1. Clinical Epidemiology Unit, West Haven Veterans Affairs Connecticut Healthcare System, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 06516, USA. terri.fried@yale.edu
Abstract
OBJECTIVES: The purpose of this study was to develop a patient-centered measure of treatment preference applicable across a range of diseases and treatment decisions. METHODS: Instrument development was based on previous research supplemented by open-ended interviews and focus groups. Psychometric properties of the instrument were determined by administration to 125 persons aged 60 or older with a limited life expectancy secondary to congestive heart failure, chronic obstructive pulmonary disease, or cancer. Test-retest and inter-rater reliability were established using intraclass correlation coefficients. Construct validity was established by examining associations of the measure with a single-item question regarding treatment goals and with age, ethnicity, and functional impairment, characteristics known to be associated with preferences. The Willingness to Accept Life-Sustaining Treatment instrument (WALT) consists of 6 scenarios in which respondents weigh treatment burden against treatment outcomes expressed in terms of the likelihood of different health states and length of life following treatment. RESULTS: Inter-rater reliability ranged from .73 to .95 and test-retest reliability from .49 to .93. WALT scores were significantly associated with a simpler measure of preference and with age, ethnicity, and functional impairment. CONCLUSIONS: The WALT measures patients' treatment preferences, assessed in the context of treatment burden and multiple aspects of treatment outcome with sound psychometric properties.
OBJECTIVES: The purpose of this study was to develop a patient-centered measure of treatment preference applicable across a range of diseases and treatment decisions. METHODS: Instrument development was based on previous research supplemented by open-ended interviews and focus groups. Psychometric properties of the instrument were determined by administration to 125 persons aged 60 or older with a limited life expectancy secondary to congestive heart failure, chronic obstructive pulmonary disease, or cancer. Test-retest and inter-rater reliability were established using intraclass correlation coefficients. Construct validity was established by examining associations of the measure with a single-item question regarding treatment goals and with age, ethnicity, and functional impairment, characteristics known to be associated with preferences. The Willingness to Accept Life-Sustaining Treatment instrument (WALT) consists of 6 scenarios in which respondents weigh treatment burden against treatment outcomes expressed in terms of the likelihood of different health states and length of life following treatment. RESULTS: Inter-rater reliability ranged from .73 to .95 and test-retest reliability from .49 to .93. WALT scores were significantly associated with a simpler measure of preference and with age, ethnicity, and functional impairment. CONCLUSIONS: The WALT measures patients' treatment preferences, assessed in the context of treatment burden and multiple aspects of treatment outcome with sound psychometric properties.
Authors: Richard A Mularski; Sydney M Dy; Lisa R Shugarman; Anne M Wilkinson; Joanne Lynn; Paul G Shekelle; Sally C Morton; Virginia C Sun; Ronda G Hughes; Lara K Hilton; Margaret Maglione; Shannon L Rhodes; Cony Rolon; Karl A Lorenz Journal: Health Serv Res Date: 2007-10 Impact factor: 3.402
Authors: Cynthia M Boyd; Jennifer L Wolff; Erin Giovannetti; Lisa Reider; Carlos Weiss; Qian-li Xue; Bruce Leff; Chad Boult; Travonia Hughes; Cynthia Rand Journal: Med Care Date: 2014-03 Impact factor: 2.983
Authors: JoAnne Alissi Cosgriff; Margaret Pisani; Elizabeth H Bradley; John R O'Leary; Terri R Fried Journal: J Gen Intern Med Date: 2007-09-14 Impact factor: 5.128
Authors: Xin Gao; Holly G Prigerson; Eli L Diamond; Baohui Zhang; Alexi A Wright; Fremonta Meyer; Paul K Maciejewski Journal: J Pain Symptom Manage Date: 2012-07-28 Impact factor: 3.612